NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

de Castro, G., Rizvi, N. A., Schmid, P., Syrigos, K., Martin, C., Yamamoto, N., Cheng, Y., Moiseyenko, V., Summers, Y., Vynnychenko, I., Lee, S. Y., Bryl, M., Zer, A., Erman, M., Timcheva, C., Raja, R., Naicker, K., Scheuring, U., Walker, J., … Mok, T. (2023). NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. Journal of Thoracic Oncology, 18(1), 106–119. https://doi.org/10.1016/j.jtho.2022.09.223
Authors:
Gilberto de Castro
Naiyer A. Rizvi
Peter Schmid
Konstantinos Syrigos
Claudio Martín
Nobuyuki Yamamoto
Ying Cheng
Vladimir Moiseyenko
Yvonne Summers
Ihor Vynnychenko
Sung Yong Lee
Maciej Bryl
Alona Zer
Mustafa Erman
Constanta Timcheva
Rajiv Raja
Kirsha Naicker
Urban Scheuring
Jill Walker
Helen Mann
Vikram K. Chand
Tony Mok
Affiliated Authors:
Naiyer A. Rizvi
Subjects:
Lung Neoplasms (MeSH)
Carcinoma, Non-Small-Cell Lung (MeSH)
Cancer Immunotherapy (OpenAlex Topic)
Advancements in Lung Cancer Research (OpenAlex Topic)
Genomic Landscape of Cancer and Mutational Signatures (OpenAlex Topic)
Author Keywords:
durvalumab
metastatic nsclc
neptune
tremelimumab
tumor mutational burden
elink
Publication Type:
Article
Unique ID:
10.1016/j.jtho.2022.09.223
PMID:
36240972
DOI:
10.1016/j.jtho.2022.09.223
Journal:
Journal of Thoracic Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record
View Web of Science Record

Record Created: